DCZ3112
DCZ3112 is a Hsp90/Cdc37 protein-protein interaction inhibitor, with a Kd value of 4.98 µM against human Hsp90. DCZ3112 binds to the N-terminal domain of Hsp90, disrupts the Hsp90-Cdc37 interaction, and does not inhibit the ATPase activity of Hsp90. DCZ3112 induces G1 phase cell cycle arrest, apoptosis, reduces the phosphorylation levels of AKT and ERK, and inhibits the proliferation of HER2-positive breast cancer cells. DCZ3112 can be used in breast cancer-related research.
For research use only. We do not sell to patients.
- CAS No.: 2556837-25-1
- Formula: C15H14ClF3N8
- Molecular Weight:398.78
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
HSP90 4.98 μM (Kd) |
Cdc37 |
ERK |
Akt |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SK-BR-3 | IC50 |
7.9 μM
|
Antiproliferative activity against human SK-BR-3 breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B (SRB) assay.
Antiproliferative activity against human SK-BR-3 breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B (SRB) assay.
|
30017966 |
| BT-474 | IC50 |
4.6 μM
|
Antiproliferative activity against human BT-474 breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B (SRB) assay.
Antiproliferative activity against human BT-474 breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B (SRB) assay.
|
30017966 |
In Vitro
DCZ3112 binds directly to recombinant full-length human Hsp90α, with a KD value of 4.98 µM[1].
DCZ3112 (20-40 µM; 12 h) reduces the protein levels of HER2, AKT and RAF-1 in BT-474 human breast cancer cells via post-transcriptional degradation rather than transcriptional inhibition[1].
DCZ3112 (72 h) potently inhibits the proliferation of HER2-positive human breast cancer cells SK-BR-3 and BT-474 (with IC50 values of 7.9 µM and 4.6 µM, respectively) as well as Geldanamycin (HY-15230)-resistant derivative cells, while it exhibits only extremely low activity against most HER2-negative human breast cancer cells[1].
DCZ3112 (5-40 µM; 12 h) induces concentration-dependent degradation of the Hsp90 client proteins HER2, AKT, RAF-1, CDK4 and CDK6 in HER2-positive human breast cancer SK-BR-3 and BT-474 cells, exerts only weak effects in HER2-negative MDA-MB-231 cells, and does not induce Hsp72 upregulation[1].
DCZ3112 (20 µM; 12 h) induces proteasome-dependent degradation of the Hsp90 client proteins HER2, AKT and RAF-1 in human breast cancer BT-474 cells[1].
Combination treatment with DCZ3112 (72 h) and Trastuzumab (HY-P9907) or Pertuzumab (HY-P9912) exerts synergistic antiproliferative effects on HER2-positive SK-BR-3, BT-474, and Trastuzumab-resistant BT-474/T human breast cancer cells, with combination index (CI) values of all regimens being <1[1].
Combination treatment with DCZ3112 (10 µM; 48 h) and 10 µg/mL Trastuzumab or Pertuzumab enhances the inhibitory effect on AKT and/or ERK phosphorylation in BT-474 human breast cancer cells compared with monotherapy[1].
DCZ3112 (5-40 μM; 12 h) induces the degradation of Hsp90 client proteins EGFR, HER2 and AKT in Trastuzumab-resistant human breast cancer cell line BT-474/T, thereby overcoming Trastuzumab resistance mediated by EGFR upregulation[1].
DCZ3112 selectively inhibits the growth of two HER2-positive breast cancer cell lines, SK-BR-3 and BT-474, with IC50 values of 7.9 μM and 4.6 μM, respectively. It also blocks oncogenic signaling pathways and overcomes Trastuzumab resistance[2].
DCZ3112 (20 µM; 24 h) induces G1-phase cell cycle arrest in HER2-positive human breast cancer cell lines SK-BR-3 and BT-474 by regulating G1-phase regulatory proteins[1].
Combination treatment with DCZ3112 (15 µM; 48 h) and 10 µg/mL Trastuzumab enhances G1-phase cell cycle arrest in human breast cancer BT-474 cells, as compared with treatment with either agent alone[1].
DC3112 (10-40 µM; 48 h) induces caspase-dependent apoptosis in HER2-positive SK-BR-3 and BT-474 human breast cancer cells, and triggers concentration-dependent cleavage of PARP, caspase-3, caspase-8 and caspase-9[1].
Combination treatment with DCZ3112 (15 µM; 72 h) and 10 µg/mL Trastuzumab or Pertuzumab enhances the apoptosis-inducing effect on human breast cancer BT-474 cells compared with DCZ3112 monotherapy[1].
DCZ3112 inhibits the interaction between Hsp90 and Cdc37, and potently suppresses the proliferation of two HER2-positive breast cancer cell lines, SK-BR-3 and BT-474, with IC50 values of 7.9 μM and 4.6 μM, respectively. It also regulates the levels of Hsp90 client proteins and downstream signaling pathways[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SK-BR-3, BT-474, and MDA-MB-231 human breast cancer cells
-
Concentration:5 µM; 10 µM; 20 µM; 40 µM
-
Incubation Time:12 h
-
Result:Downregulated Hsp90 client proteins HER2, AKT, RAF-1, CDK4, and CDK6 in a concentration-dependent manner in SK-BR-3 and BT-474 cells, and exerted weaker effects in HER2-negative MDA-MB-231 cells.
Showed no upregulation of Hsp72 (a hallmark of traditional Hsp90 inhibition).
-
Cell Line:BT-474 human breast cancer cells
-
Concentration:20 µM; 40 µM
-
Incubation Time:12 h
-
Result:Did not inhibit transcription of HER2, AKT, or RAF-1 mRNA.
-
Cell Line:SK-BR-3 and BT-474 human breast cancer cells
-
Concentration:20 µM
-
Incubation Time:24 h
-
Result:Induced G1-phase cell-cycle arrest in SK-BR-3 and BT-474 cells, accompanied by downregulation of G1-related proteins P-Rb, CDK4, and Cyclin D1, and upregulation of P21.
-
Cell Line:SK-BR-3 and BT-474 human breast cancer cells
-
Concentration:10 µM; 20 µM; 40 µM
-
Incubation Time:48 h
-
Result:Induced a concentration-dependent increase in cleavage of PARP, caspase-3, caspase-8, and caspase-9 in SK-BR-3 and BT-474 cells.
-
Cell Line:BT-474 human breast cancer cells
-
Concentration:15 µM DCZ3112; 10 µg/mL Trastuzumab; 10 µg/mL Pertuzumab
-
Incubation Time:48 h
-
Result:Increased the percentage of G1-phase cells from 69.7% (DCZ3112 alone) or 69.9% (Trastuzumab alone) to 81.8% when combined with Trastuzumab; showed no significant enhancement when combined with Pertuzumab.
-
Cell Line:BT-474 human breast cancer cells
-
Concentration:15 µM DCZ3112; 10 µg/mL Trastuzumab; 10 µg/mL Pertuzumab
-
Incubation Time:72 h
-
Result:Enhanced apoptosis induction when combined with Trastuzumab or Pertuzumab compared to DCZ3112 treatment alone, while neither Trastuzumab nor Pertuzumab alone induced detectable apoptosis.
-
Cell Line:BT-474 human breast cancer cells
-
Concentration:10 µM DCZ3112; 10 µg/mL Trastuzumab; 10 µg/mL Pertuzumab
-
Incubation Time:48 h
-
Result:Induced a greater reduction in AKT phosphorylation when combined with Trastuzumab or Pertuzumab compared to any agent alone; synergistically inhibited ERK phosphorylation when combined with Trastuzumab.
-
Cell Line:Trastuzumab-resistant BT-474/T human breast cancer cells
-
Concentration:5 µM; 10 µM; 20 µM; 40 µM
-
Incubation Time:12 h
-
Result:Decreased EGFR, HER2, and AKT protein levels in BT-474/T cells, similar to its effects in parental BT-474 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/cA-nude (female, 5-6 weeks old)[1]
-
Dosage:70 mg/kg
-
Administration:i.p.; daily; 18 days
-
Result:Inhibited tumor growth by 61% (p < 0.01) on the final treatment day.
Decreased levels of Hsp90 client proteins HER2 and AKT in tumor tissue.
Produced enhanced antitumor efficacy (p < 0.05) when combined with Trastuzumab, including regression of one of six tumors.
Caused synergistic reduction in AKT and ERK phosphorylation in tumor tissues when combined with Trastuzumab.
Was rapidly detected in plasma and tumor tissue after a single 70-mg/kg i.p. dose, remained detectable for 24 hours, and suppressed HER2 and AKT levels in tumor tissue for at least 24 hours.
Was well tolerated with no significant body weight loss.
Chemical Information
-
CAS No. 2556837-25-1
-
Molecular Weight 398.78
-
Formula C15H14ClF3N8
-
SMILES
FC(F)(F)C1=CC(=CC=C1Cl)NC2=NC(=NN)N=C(N2)N3N=C(C=C3C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay
Bimolecular fluorescence complementation detects protein-protein proximity in living or fixed cells by fusing two candidate interaction partners to nonfluorescent N- and C-terminal fragments of a fluorescent protein; when the partners interact or remain close enough, the fluorescent fragments complement, mature, and generate a fluorescent signal at the site of the protein complex. The BiFC readout is fluorescence intensity and subcellular localization of the reconstituted fluorophore, which reflects formation or stabilization of a protein complex rather than direct biochemical binding kinetics; BiFC is therefore useful for mapping where interactions occur in cancer cells, neurons, macrophages, organoid-derived cells, or drug-screening systems, but results should be validated by independent assays such as co-IP or Western blot. BiFC signal formation is delayed by fluorophore maturation and can stabilize otherwise transient complexes, so it is not a real-time reversible interaction assay
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Pull-down
The pull-down assay is an in vitro technique used to detect physical interactions between two or more proteins and an invaluable tool for confirming a predicted protein-protein interaction or identifying novel interacting partners. This method typically involves the use of affinity purification with various wash and elution steps.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
Protocol for Yeast Two-Hybrid (Y2H) Assay
The yeast two-hybrid assay detects binary protein-protein interactions by separating a transcription factor into a DNA-binding domain fused to a "bait" protein and a transcriptional activation domain fused to a "prey" protein; if bait and prey interact in yeast, the transcription factor is reconstituted and activates reporter genes such as HIS3, ADE2, lacZ, MEL1, or other selectable/readable reporters. The readout is yeast growth on selective medium and/or reporter activity, which reflects proximity-dependent transcriptional activation in the yeast nucleus rather than direct biochemical binding in the original mammalian, tumor, neuronal, macrophage, or organoid context. Because yeast two-hybrid can generate false positives and false negatives, interaction claims should be validated using independent assays such as co-immunoprecipitation, Western blot, immunofluorescence colocalization, BiFC, pull-down, or mammalian two-hybrid assays.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- DCZ3112
- 2556837-25-1
- DCZ 3112
- DCZ-3112
- HSP
- Akt
- ERK
- Apoptosis
- trastuzumab-resistant HER2-positive breast cancer
- apoptosis
- HER2-positive breast cancer cells
- SK-BR-3 human breast cancer cells
- Hsp90
- G1-phase cell cycle arrest
- Cdc37
- BT-474 human breast cancer cells
- xenografts
- Hsp90 client proteins
- Inhibitor
- inhibitor
- inhibit